HC Wainwright & Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:SRZN) with a Buy and

Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 202

Surrozen NASDAQ: SRZN Chief Executive Officer Craig Parker outlined the company's rationale for deve

SOUTH SAN FRANCISCO, Calif. , July 15, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "C

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Com

HC Wainwright & Co. analyst Matthew Caufield maintains Surrozen (NASDAQ:SRZN) with a Buy and

On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of

SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “C

Surrozen (NASDAQ: SRZN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both sm

Surrozen (SRZN) saw its shares surge in the last session with trading volume being higher than avera

Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc acquired

HC Wainwright & Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:SRZN) with a Buy and

Surrozen (NASDAQ:SRZN) reported quarterly losses of $(20.13) per share which missed the analyst cons

Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2

Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc acquired

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Co

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Co

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Surrozen (NASDAQ:SRZN) with a Ove

Surrozen (NASDAQ: SRZN - Get Free Report) and Galmed Pharmaceuticals (NASDAQ: GLMD - Get Free Report

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Co

Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III bought 18,0

Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III purchased 1

Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey purchased 11,893 shares of Surr

Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey purchased 18,052 shares of the

Surrozen (NASDAQ:SRZN) reported quarterly losses of $(8.36) per share which missed the analyst conse

On October 14, 2025, Surrozen, Inc. (the "Company") received notice from TCGFB, Inc. ("T

Surrozen (NASDAQ:SRZN) reported quarterly earnings of $2.55 per share which beat the analyst consens

Newly granted patent is part of the expanding intellectual property portfolio directed to:-generatin

HC Wainwright & Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:SRZN) with a Buy and

Surrozen (NASDAQ:SRZN) reported quarterly losses of $(7.43) per share which missed the analyst conse

HC Wainwright & Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:SRZN) with a Buy and

Surrozen (NASDAQ:SRZN) reported quarterly losses of $(21.67) per share which missed the analyst cons

HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Surrozen (NASDAQ:SRZN) wit

Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company

Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) shares jumped 58% to $1.88 after the compan

Companies Reporting Before The Bell • Boyd Gaming (NYSE:BYD) is estimated to report quarterly earni

Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Techn

Gainers Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company

Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announce

Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares rose 158% to $2.42 in pre-market trading after

Gainers AIM ImmunoTech Inc. (NYSE: AIM) shares rose 82.4% to $0.62 in pre-market trading. AIM Imm

Upgrades

Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, s